Showing 641-650 of 1365 results for "".
- Crown Labs Adds to Portfolio with Acquisition of Keri from GSKhttps://practicaldermatology.com/news/crown-labs-adds-to-portfolio-with-acquisition-of-keri-from-gsk/2460017/Crown Laboratories, Inc. acquired the North American rights for Keri from GlaxoSmithKline (GSK). The acquisition of Keri from GSK marks the sixth product from GSK that Crown has acquired in the past five months. “Acqui
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Key West Bans Sunscreens with Oxybenzone and Octinoxatehttps://practicaldermatology.com/news/key-west-bans-sunscreens-with-oxybenzone-and-octinoxate/2459911/Following Hawaii’s lead, Florida’s Key West City Commission voted to ban the sale of products that contain oxybenzone or octinoxate — two chemicals in sunscreen that have been shown to wash off and potentially damage coral reefs. The ban takes effect in January 2021. Fir
- Keloids May Up Breast Cancer Riskhttps://practicaldermatology.com/news/keloids-may-up-breast-cancer-risk/2459925/Keloids may be associated with an increased risk breast cancer, particularly among African Americans, a new study suggests. The research team hypothesized African American women with a history of keloids would reflect a population of breast cancer patients with aggressive tumors and poor
- JAK Kinase Inhibitors Show Promise in Treating Alopeciahttps://practicaldermatology.com/news/jak-kinase-inhibitors-show-promise-in-treating-alopecia/2459947/UPDATED -- New research suggests selective oral JAK kinase inhibitors may play a role in treating moderate-to-severe alopecia areata (AA). The findings were presented at the Inflammatory Skin Disease Summit in Vienna, Austria. In this
- Low 3% Keloid Recurrence Found in Multicenter Case Series of Patients Treated with SRThttps://practicaldermatology.com/news/low-3-keloid-recurrence-found-in-multicenter-case-series-of-patients-treated-with-srt/2457488/Sensus Healthcare, Inc., a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), shared positive results of a multicenter case series of patients treated with the SRT-100 following
- Cosmetic Surgery Forum Kicks Off in Las Vegashttps://practicaldermatology.com/news/cosmetic-surgery-forum-kicks-off-in-las-vegas/2457493/With new and returning faculty, controversial and timely topics, and an all new venue, Cosmetic Surgery Forum (CSF) kicks off its 10th year at the chic Cosmopolitan Hotel. The meeting features 50 sessions and a robust exhibit floor. This year’s Cosmetic Surgery Foru
- Actress Kristin Davis Partners with Coolsculpting for Denim Denial Programhttps://practicaldermatology.com/news/actress-kirstin-davis-partners-with-coolsculpting-for-denim-denial-program/2457532/"Sex and the City” star Kristin Davis is partnering with CoolSculpting for the new "Denim Denial" consumer program. Denim Denial recognizes that every woman has a pair of jeans on the top shelf of her closet or tucked away in a bottom drawer but is holding on to
- Kuleana Debuts Natural, Reef-Safe Sunscreenhttps://practicaldermatology.com/news/kuleana-debuts-natural-reef-safe-sunscreen/2457601/Amid growing concerns that certain sunscreen ingredients are harming coral reefs and marine life, Hawaiian company Kuleana is rolling out a natural sunscreen that is free from oxybenzone and octinoxate – two chemicals known to be toxic to corals and other marine life that were recently bann
- Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpointshttps://practicaldermatology.com/news/almirall-phase-3-studies-of-kx2-391-for-ak-meet-primary-endpoints/2457676/Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study achieved statistical significance on this endpoint. The double-blind, randomized, vehi